196 related articles for article (PubMed ID: 7628878)
1. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
2. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
3. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
5. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.
Reiter Y; Brinkmann U; Webber KO; Jung SH; Lee B; Pastan I
Protein Eng; 1994 May; 7(5):697-704. PubMed ID: 8073039
[TBL] [Abstract][Full Text] [Related]
6. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
8. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
9. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
10. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
11. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
13. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Brinkmann U; Reiter Y; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7538-42. PubMed ID: 8356052
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
16. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
17. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
Kuan CT; Pastan I
Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells.
Nagai T; Tanaka M; Tsuneyoshi Y; Matsushita K; Sunahara N; Matsuda T; Yoshida H; Komiya S; Onda M; Matsuyama T
Arthritis Rheum; 2006 Oct; 54(10):3126-34. PubMed ID: 17009233
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
20. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
